Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for Cutaneous Lesions in Neurofibromatosis 1
NCT02332902Phase 2Completed
- Sponsor
- UTHealth Houston
- Start
- Feb 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in neurofibromatosis type 1 (NF1), sponsored by UTHealth Houston. Started Feb 2015; status: completed.
02
Drugs
everolimus
03
Conditions
neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on NCT02332902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02332902.